In search of CML stem cells' deadly weakness

Current Hematologic Malignancy Reports

Volumn 6, Issue 2, 2011, Pages 82-87

  Pellicano, Francesca ^a   Sinclair, Amy ^a   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

BCR ABL; BMI1; CD34+ CD38 cells; Chronic myeloid leukemia; FOXOs; Haematopoietic stem cells; HSC; IL1RAP; Immune therapy; JAK2; MicroRNA; miR 203; miR 328; Philadelphia chromosome; PML; PP2A; Quiescence; TGF ; TKIs; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; BMI1 PROTEIN; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; JANUS KINASE 2; MICRORNA; PHOSPHOPROTEIN PHOSPHATASE 2A; PROMYELOCYTIC LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR FOXO;

ARTICLE; CHRONIC MYELOID LEUKEMIA; ERADICATION THERAPY; HUMAN; MEDICAL RESEARCH; PATHOGENESIS; RNA DEGRADATION; STEM CELL;

FORKHEAD TRANSCRIPTION FACTORS; FUSION PROTEINS, BCR-ABL; HUMANS; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICRORNAS; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS;

EID: 79957453355     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0085-y     Document Type: Article

References (52)

1. R Ren 2005 Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia Nat Rev Cancer 5 3 172 83 15719031 10.1038/nrc1567 1:CAS:528:DC%2BD2MXhslSnt7g%3D (Pubitemid 40314949)
2. HM Kantarjian JE Cortes S O'Brien, et al. 2003 Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses Blood 101 1 97 100 12393600 10.1182/blood-2002-02-0545 1:CAS:528:DC%2BD3sXhtFSqug%3D%3D (Pubitemid 36025893)
3. G Saglio DW Kim S Issaragrisil, et al. 2010 Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 24 2251 9 20525993 10.1056/NEJMoa0912614 1:CAS:528:DC%2BC3cXnvVaktbk%3D
4. HA Bradeen CA Eide T O'Hare, et al. 2006 Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations Blood 108 7 2332 8 16772610 10.1182/blood-2006-02-004580 1:CAS:528:DC%2BD28XhtVCgur%2FJ (Pubitemid 44497517)
5. R Bhatia M Holtz N Niu, et al. 2003 Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood 101 12 4701 7 12576334 10.1182/blood-2002-09-2780 1:CAS:528:DC%2BD3sXkslequ7o%3D (Pubitemid 36857723)
6. AL Su Chu T McDonald DS Snyder, et al. 2008 Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years [abstract] Blood (ASH Annual Meeting Abstracts) 112 194
7. FX Mahon D Rea J Guilhot, et al. 2010 Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 11 1029 35 20965785 10.1016/S1470-2045(10)70233-3 1:CAS:528:DC%2BC3cXhtlKmtrnP This work investigates the possibility of discontinuing IM treatment in patients with a complete molecular remission of at least 2 years' duration.
8. GV Helgason A Hamilton S Myssina, et al. 2010 Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia (CML)? [abstract]. Br J Haematol (BSH Annual Meeting Abstracts) 149 178
9. AS Corbin A Agarwal M Loriaux J Cortes MW Deininger BJ Druker 2011 Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity J Clin Invest 121 396 409 21157039 10.1172/JCI35721 1:CAS:528:DC%2BC3MXis1yltA%3D%3D This paper suggests that primitive CML cells are not oncogene-addicted and that therapies that target BCR-ABL will not eliminate CML stem cells
10. T Skorski P Kanakaraj M Nieborowska-Skorska, et al. 1995 Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells Blood 86 2 726 36 7606002 1:CAS:528:DyaK2MXmvVyhu7o%3D
11. Z Tothova DG Gilliland 2007 FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system Cell Stem Cell 1 2 140 52 18371346 10.1016/j.stem.2007.07.017 1:CAS:528:DC%2BD2sXhtVSnsrvI (Pubitemid 47215597)
12. K Naka T Hoshii T Muraguchi, et al. 2010 TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia Nature 463 7281 676 80 20130650 10.1038/nature08734 1:CAS:528:DC%2BC3cXhsVygtL4%3D This paper highlights the importance of the FOXO transcription factor family and TGF-β in CML development
13. SM Graham HG Jorgensen E Allan, et al. 2002 Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 1 319 25 11756187 10.1182/blood.V99.1. 319 1:CAS:528:DC%2BD38XivF2gug%3D%3D (Pubitemid 34532999)
14. F Pellicano GV Helgason E Allan, et al. 2010 FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells [abstract] Haematologica (EHA Annual Meeting Abstract) 95 Suppl 1 48
15. S Fernan de zdeMattos A Essafi I Soeiro, et al. 2004 FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism Mol Cell Biol 24 22 10058 71 10.1128/MCB.24.22.10058-10071.2004 1:CAS:528: DC%2BD2cXpslOms70%3D (Pubitemid 39458829)
16. N Komatsu T Watanabe M Uchida, et al. 2003 A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells J Biol Chem 278 8 6411 19 12456669 10.1074/jbc.M211562200 1:CAS:528:DC%2BD3sXht1ejs70%3D (Pubitemid 36800899)
17. K Ito R Bernardi A Morotti, et al. 2008 PML targeting eradicates quiescent leukaemia-initiating cells Nature 453 7198 1072 8 18469801 10.1038/nature07016 1:CAS:528:DC%2BD1cXntlGjtb0%3D This paper highlights the importance of PML in CML development and suggests possible treatments with arsenic-based agents (Pubitemid 351871736)
18. M Jaras P Johnels N Hansen, et al. 2010 Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein Proc Natl Acad Sci USA 107 37 16280 5 20805474 10.1073/pnas.1004408107 1:CAS:528:DC%2BC3cXhtF2gsb7J
19. S Subramaniam C Stansberg C Cunningham 2004 The interleukin 1 receptor family Dev Comp Immunol 28 5 415 28 15062641 10.1016/j.dci.2003.09.016 1:CAS:528:DC%2BD2cXhtFCjtL8%3D (Pubitemid 38177445)
20. JJ Schuringa E Vellenga 2010 Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells Curr Opin Hematol 17 4 294 9 20308890 10.1097/MOH.0b013e328338c439 1:CAS:528:DC%2BC3cXnvVOnsr4%3D
21. J Lessard S Baban G Sauvageau 1998 Stage-specific expression of polycomb group genes in human bone marrow cells Blood 91 4 1216 24 9454751 1:CAS:528:DyaK1cXhtVGksrg%3D (Pubitemid 28086874)
22. J Lessard A Schumacher U Thorsteinsdottir, et al. 1999 Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation Genes Dev 13 20 2691 703 10541555 10.1101/gad.13.20.2691 1:CAS:528:DyaK1MXnt1Wqs70%3D (Pubitemid 29508556)
23. IK Park D Qian M Kiel, et al. 2003 Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells Nature 423 6937 302 5 12714971 10.1038/nature01587 1:CAS:528:DC%2BD3sXjs1ynur4%3D (Pubitemid 40852701)
24. NM van der Lugt J Domen K Linders, et al. 1994 Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene Genes Dev 8 7 757 69 7926765 10.1101/gad.8.7.757
25. A Iwama H Oguro M Negishi, et al. 2004 Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1 Immunity 21 6 843 51 15589172 10.1016/j.immuni.2004.11.004 1:CAS:528:DC%2BD2MXjvFGjtA%3D%3D (Pubitemid 39626674)
26. A Rizo B Dontje E Vellenga, et al. 2008 Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1 Blood 111 5 2621 30 18156489 10.1182/blood-2007-08-106666 1:CAS:528:DC%2BD1cXivFaktL4%3D
27. M Mohty AS Yong RM Szydlo, et al. 2007 The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia Blood 110 1 380 3 17360938 10.1182/blood-2006-12-065599 1:CAS:528:DC%2BD2sXnsVait78%3D (Pubitemid 47026858)
28. A Rizo SJ Horton S Olthof, et al. 2010 BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells Blood 116 22 4621 30 20724541 10.1182/blood-2010-02-270660 1:CAS:528:DC%2BC3cXhsFGgtbjO
29. M van Lohuizen S Verbeek B Scheijen, et al. 1991 Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging Cell 65 5 737 52 1904008 10.1016/0092-8674(91)90382-9 (Pubitemid 121001306)
30. R Kralovics F Passamonti AS Buser, et al. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 17 1779 90 15858187 10.1056/NEJMoa051113 1:CAS:528:DC%2BD2MXjsFyhsLw%3D (Pubitemid 40570926)
31. M Sattler R Salgia 1997 Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL Cytokine Growth Factor Rev 8 1 63 79 9174663 10.1016/S1359-6101(96)00047-0 1:STN:280:DyaK2szhslKrsg%3D%3D (Pubitemid 27214689)
32. X Jiang A Lopez T Holyoake, et al. 1999 Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia Proc Natl Acad Sci USA 96 22 12804 9 10536003 10.1073/pnas.96.22.12804 1:CAS:528:DyaK1MXnt1yqtro%3D (Pubitemid 29513583)
33. H Neubauer A Cumano M Muller, et al. 1998 Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis Cell 93 3 397 409 9590174 10.1016/S0092-8674(00)81168-X 1:CAS:528:DyaK1cXjtFCjtLk%3D (Pubitemid 28232084)
34. E Parganas D Wang D Stravopodis, et al. 1998 Jak2 is essential for signaling through a variety of cytokine receptors Cell 93 3 385 95 9590173 10.1016/S0092-8674(00)81167-8 1:STN:280:DyaK1c3ltVSmtw%3D%3D (Pubitemid 28232083)
35. S Xie Y Wang J Liu, et al. 2001 Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation Oncogene 20 43 6188 95 11593427 10.1038/sj.onc.1204834 1:CAS:528:DC%2BD3MXnsFOiuro%3D (Pubitemid 32964431)
36. S Xie H Lin T Sun RB Arlinghaus 2002 Jak2 is involved in c-Myc induction by Bcr-Abl Oncogene 21 47 7137 46 12370803 10.1038/sj.onc.1205942 1:CAS:528:DC%2BD38XnsFyksr0%3D (Pubitemid 35305600)
37. AK Samanta H Lin T Sun, et al. 2006 Janus kinase 2: a critical target in chronic myelogenous leukemia Cancer Res 66 13 6468 72 16818614 10.1158/0008-5472.CAN-06-0025 1:CAS:528:DC%2BD28XmsVamsbg%3D (Pubitemid 44085597)
38. AK Samanta SN Chakraborty Y Wang, et al. 2009 Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients Oncogene 28 14 1669 81 19234487 10.1038/onc.2009.7 1:CAS:528:DC%2BD1MXktFOit7o%3D The authors demonstrate that JAK2 inhibition induces apoptosis in CML cells from patients in all phases, including those that failed IM
39. AK Samanta SN Chakraborty Y Wang, et al. 2010 Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML) Genes Cancer 19;1 4 346 59 10.1177/1947601910372232
40. A Hamilton P Gallipoli E Nicholson TL Holyoake 2010 Targeted therapy in haematological malignancies J Pathol 220 4 404 18 20041451 1:CAS:528: DC%2BC3cXjsFent7s%3D
41. J Westermarck WC Hahn 2008 Multiple pathways regulated by the tumor suppressor PP2A in transformation Trends Mol Med 14 4 152 60 18329957 10.1016/j.molmed.2008.02.001 1:CAS:528:DC%2BD1cXktlCktLo%3D
42. P Neviani R Santhanam R Trotta, et al. 2005 The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein Cancer Cell 8 5 355 68 16286244 10.1016/j.ccr.2005.10.015 1:CAS:528:DC%2BD2MXht12gsbvJ (Pubitemid 41579831)
43. P Neviani R Santhanam JJ Oaks, et al. 2007 FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia J Clin Invest 117 9 2408 21 17717597 10.1172/JCI31095 1:CAS:528:DC%2BD2sXhtVCms7vM (Pubitemid 47494343)
44. P Neviani R Santhanam Y Ma, et al. 2008 Activation of PP2A by FTY720 inhibits survival and self-renewal of the Ph+ chronic myelogenous leukemia (CML) CD34+/CD38- stem cell through the simultaneous suppression of BCR/ABL and BCR/ABL-independent signals [abstract] Blood (ASH Annual Meeting Abstracts) 112 189
45. RA Shivdasani 2006 MicroRNAs: regulators of gene expression and cell differentiation Blood 108 12 3646 53 16882713 10.1182/blood-2006-01-030015 1:CAS:528:DC%2BD28Xht1Kgs77K (Pubitemid 44864540)
46. AM Eiring JG Harb P Neviani, et al. 2010 miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts Cell 140 5 652 65 20211135 10.1016/j.cell.2010.01.007 1:CAS:528: DC%2BC3cXlsVSgtr0%3D This paper describes for the first time the dual activity of miR-328 in controlling cell fate through association with mRNA targets and through its decoy role
47. CZ Chen L Li HF Lodish DP Bartel 2004 MicroRNAs modulate hematopoietic lineage differentiation Science 303 5654 83 6 14657504 10.1126/science.1091903 1:CAS:528:DC%2BD3sXhtVWhs7zE (Pubitemid 38055775)
48. L Venturini K Battmer M Castoldi, et al. 2007 Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells Blood 109 10 4399 405 17284533 10.1182/blood-2006-09-045104 1:CAS:528:DC%2BD2sXls1amsLo%3D (Pubitemid 46743409)
49. MJ Bueno I Perez de Castro M Gomez de Cedron, et al. 2008 Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression Cancer Cell 13 6 496 506 18538733 10.1016/j.ccr.2008.04.018 1:CAS:528:DC%2BD1cXns1yhtbs%3D (Pubitemid 351763902)
50. HG Jorgensen EK Allan NE Jordanides, et al. 2007 Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells Blood 109 9 4016 19 17213283 10.1182/blood-2006-11-057521 1:CAS:528:DC%2BD2sXkvFCiurc%3D (Pubitemid 46641755)
51. M Copland A Hamilton LJ Elrick, et al. 2006 Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood 107 11 4532 9 16469872 10.1182/blood-2005-07-2947 1:CAS:528:DC%2BD28Xlt1CgtrY%3D (Pubitemid 43801382)
52. DM Ross T Hughes JV Melo 2011 Do we have to kill the last CML cell? Leukemia 25 193 200 20844563 10.1038/leu.2010.197 1:CAS:528:DC%2BC3MXhs1amsL8%3D